2025
Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee.
Esteso P, Auerbach S, Bansal N, Harris R, Soslow J, Birnbaum B, Conway J, Cripe L, Nandi D, Hayes E, Gambetta K, Hall E, Hsu D, Kaufman B, Rosenthal D, Kirmani S, Ploutz M, Lal A, Peng D, Villa C, Shugh S, Wittlieb-Weber C, Shih R. Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee. Cardiology In The Young 2025, 1-6. PMID: 40012319, DOI: 10.1017/s1047951125000587.Peer-Reviewed Original ResearchDuchenne muscular dystrophyCardiac medicationsMuscular dystrophyCardiac careAdvanced Cardiac Therapies Improving Outcomes NetworkManagement of Duchenne muscular dystrophyImprove cardiac outcomesLoss of dystrophinAmerican College of CardiologyOptimal therapeutic efficacyExpert opinion statementsAmerican Heart AssociationCardiac outcomesImprove cardiac prognosisCardiomyopathy progressionTherapeutic efficacyCardiac prognosisHeart AssociationDisease progressionCardiac treatmentConsensus recommendationsOutcomes NetworkAmerican CollegeDystrophyCardiomyopathyAcute Systemic Sclerosis-Associated Cardiomyopathy That Improved With Glucocorticoids and Cyclophosphamide
Gustafson A, Trinh K, Lomasney J, Shah S, Hinchcliff M. Acute Systemic Sclerosis-Associated Cardiomyopathy That Improved With Glucocorticoids and Cyclophosphamide. JACC Case Reports 2025, 30: 102948. PMID: 39972702, PMCID: PMC11862153, DOI: 10.1016/j.jaccas.2024.102948.Peer-Reviewed Original ResearchSystemic sclerosisEndomyocardial biopsyDiffuse cutaneous systemic sclerosisCutaneous systemic sclerosisAssociated with increased mortalityT lymphocyte infiltrationAcute heart failureIntravenous cyclophosphamideDiagnosing myocarditisDiastolic dysfunctionSystolic dysfunctionT lymphocytesHeart failureProlonged recoveryPatientsCardiomyopathy treatmentCyclophosphamideBiopsyCardiomyopathyGlucocorticoidDysfunctionMyopericarditisMyocarditis
2024
Takotsubo cardiomyopathy and cardiogenic shock due to hypokalaemic rhabdomyolysis
Hwang E, Namburar S, Siegel M, Sanchez A. Takotsubo cardiomyopathy and cardiogenic shock due to hypokalaemic rhabdomyolysis. BMJ Case Reports 2024, 17: e261456. PMID: 39419603, DOI: 10.1136/bcr-2024-261456.Peer-Reviewed Original ResearchConceptsTakotsubo cardiomyopathyCardiogenic shockAssociated with Takotsubo cardiomyopathyConsistent with cardiogenic shockConsistent with takotsubo cardiomyopathyTriggers of takotsubo cardiomyopathyCentral venous oxygen saturationInfluence cardiac morbidityChronic idiopathic constipationLow central venous oxygen saturationST-segment elevationVenous oxygen saturationWorsening cardiomyopathyGlobal hypokinesisPrognostic significanceCardiac morbidityIdiopathic constipationSpiked helmet signSegment elevationECG patternOxygen saturationCardiomyopathyRhabdomyolysisEchocardiographyEating disordersImpact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy Results From SEQUOIA-HCM
Maron M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Arad M, Cardim N, Choudhury L, Claggett B, Coats C, Düngen H, Garcia-Pavia P, Hagège A, Januzzi J, Kulac I, Lee M, Lewis G, Ma C, Michels M, Oreziak A, Owens A, Spertus J, Solomon S, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby D, Heitner S, Kupfer S, Malik F, Meng L, Wohltman A, Olivotto I, Investigators S. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy Results From SEQUOIA-HCM. Journal Of The American College Of Cardiology 2024, 84: 1821-1831. PMID: 39352339, DOI: 10.1016/j.jacc.2024.09.003.Peer-Reviewed Original ResearchObstructive hypertrophic cardiomyopathyN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideSeptal reduction therapyHypertrophic cardiomyopathyNatriuretic peptideReduction therapySymptomatic obstructive hypertrophic cardiomyopathyExercise capacityCardiac myosin inhibitorProportion of patientsTreatment of patientsHemodynamic responseAssociated with substantial improvementsOutflow gradientPlacebo groupAficamtenEnhanced exercise capacityClinical efficacyEfficacy measuresClinical impactPlaceboResponder analysisPatientsCardiomyopathyUnraveling the genetic tapestry of pediatric sarcomeric cardiomyopathies and masquerading phenocopies in Jordan
Azab B, Aburizeg D, Shaaban S, Ji W, Mustafa L, Isbeih N, Al-Akily A, Mohammad H, Jeffries L, Khokha M, Lakhani S, Al-Ammouri I. Unraveling the genetic tapestry of pediatric sarcomeric cardiomyopathies and masquerading phenocopies in Jordan. Scientific Reports 2024, 14: 15141. PMID: 38956129, PMCID: PMC11219879, DOI: 10.1038/s41598-024-64921-9.Peer-Reviewed Original ResearchConceptsExome sequencingSarcomere-related genesMitochondrial-related diseasesAt-risk family membersGenetic architectureGenetic landscapePathogenic variantsGene panelPediatric cardiomyopathyMolecular underpinningsGenetic testingPhenocopiesSarcomeric cardiomyopathiesGenesSequenceStorage disorderFamily membersAt-riskVariantsEarly interventionExomeFamilyGlycogen storage disorderHypertrophic cardiomyopathyCardiomyopathyAre Cardiac Myosin Inhibitors Useful in Patients With Hypertrophic Obstructive Cardiomyopathy and Comorbid Hypertension? ∗
Sikand N, Sen S. Are Cardiac Myosin Inhibitors Useful in Patients With Hypertrophic Obstructive Cardiomyopathy and Comorbid Hypertension? ∗. JACC Heart Failure 2024, 12: 580-582. PMID: 38448152, DOI: 10.1016/j.jchf.2023.12.021.Commentaries, Editorials and Letters
2023
Chronic diastolic stretch unmasks conduction defects in an in vitro model of arrhythmogenic cardiomyopathy
Ng R, Gokhan I, Stankey P, Akar F, Campbell S. Chronic diastolic stretch unmasks conduction defects in an in vitro model of arrhythmogenic cardiomyopathy. AJP Heart And Circulatory Physiology 2023, 325: h1373-h1385. PMID: 37830983, PMCID: PMC10977872, DOI: 10.1152/ajpheart.00709.2022.Peer-Reviewed Original ResearchArrhythmogenic cardiomyopathyDiastolic stretchConduction deficitsConduction velocityIntensity of exerciseAction potential parametersDifferent time pointsDisease progressionHigh afterloadContractile functionHemodynamic parametersProgressive disorderUnderlying pathomechanismsArrhythmia vulnerabilityConduction defectsPhysiological shorteningHeart tissueConnexin 43Time pointsERK signalingCardiomyopathyLysosome activityCardiac cycleDesmosomal proteinsExerciseIntra-Aortic Balloon Pump Exacerbates Left Ventricular Outflow Tract Obstruction in a Patient With Takotsubo and Hypertrophic Cardiomyopathy
Griffin M, Odanovic N, McNamara R, Altin S, Balan S, Thompson J, Young L. Intra-Aortic Balloon Pump Exacerbates Left Ventricular Outflow Tract Obstruction in a Patient With Takotsubo and Hypertrophic Cardiomyopathy. Case 2023, 7: 502-507. PMID: 38197115, PMCID: PMC10772928, DOI: 10.1016/j.case.2023.07.003.Peer-Reviewed Original ResearchBaseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics
Altibi A, Alani A, Zhao Y, Masri A. Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics. Current Cardiology Reports 2023, 25: 583-595. PMID: 37103749, DOI: 10.1007/s11886-023-01883-w.Peer-Reviewed Original ResearchConceptsCardiac myosin inhibitorCardiac magnetic resonance imagingHypertrophic cardiomyopathyCare of patientsClinical trialsPathophysiology of hypertrophic cardiomyopathyCardiac magnetic resonanceNew drug therapiesHypertrophic cardiomyopathy diagnosisActin-myosin cross-bridgesLongitudinal imagingMagnetic resonance imagingMyosin inhibitorTherapeutic optionsAbstract PurposeDrug therapyOral moleculesLongitudinal imaging modalityCardiomyopathyPatientsMonitoring patientsImaging modalitiesResonance imagingInvestigate new drug therapiesSarcomere levelOutcomes of Status 4 Heart Transplant Candidates: A Nationwide Analysis
Jarrett C, Mahmoud O, Abu-Omar Y, Elgudin Y, Hussian O, Pelletier M, Sabik J, ElAmm C. Outcomes of Status 4 Heart Transplant Candidates: A Nationwide Analysis. The Journal Of Heart And Lung Transplantation 2023, 42: s282. DOI: 10.1016/j.healun.2023.02.643.Peer-Reviewed Original ResearchStatus 4Re-transplantWaitlist survivalHeart diseaseTwo-thirds of patientsCongenital heart diseaseKaplan-Meier methodLog-rank testInotrope-dependent patientsHeart transplant candidatesIschemic heart diseaseNationwide analysisInotrope dependencePrimary endpointIschemic cardiomyopathyHeart transplantationIV inotropesTransplantationUnique patientsTransplant candidatesInotropesPatientsSurvivalCardiomyopathyMonthsEngineered cardiac tissue model of restrictive cardiomyopathy for drug discovery
Wang B, Nash T, Zhang X, Rao J, Abriola L, Kim Y, Zakharov S, Kim M, Luo L, Morsink M, Liu B, Lock R, Fleischer S, Tamargo M, Bohnen M, Welch C, Chung W, Marx S, Surovtseva Y, Vunjak-Novakovic G, Fine B. Engineered cardiac tissue model of restrictive cardiomyopathy for drug discovery. Cell Reports Medicine 2023, 4: 100976. PMID: 36921598, PMCID: PMC10040415, DOI: 10.1016/j.xcrm.2023.100976.Peer-Reviewed Original ResearchConceptsRestrictive cardiomyopathyElevated ventricular filling pressuresVentricular filling pressurePrecision medicine approachVariety of cardiomyopathiesPluripotent stem cell-derived cardiomyocytesStem cell-derived cardiomyocytesDiastolic relaxationCardiomyocyte relaxationFilamin CMyocardial relaxationCell-derived cardiomyocytesFilling pressurePotential therapyRelaxation velocityMyocardial stiffnessCalcium kineticsMedicine approachCardiomyopathyTranslational potentialIsogenic control linesCardiac tissuePassive tensionScreening identifiesTissue modelINTRA- AND INTER-OBSERVER VARIABILITY IN LEFT ATRIAL STRAIN ANALYSIS IN PATIENTS WITH AMYLOID CARDIOMYOPATHY
Majid M, Akintoye E, Yaker Z, Karmali R, Syed A, Agrawal A, Kumar A, Hanna M, Moudgil R, Klein A. INTRA- AND INTER-OBSERVER VARIABILITY IN LEFT ATRIAL STRAIN ANALYSIS IN PATIENTS WITH AMYLOID CARDIOMYOPATHY. Journal Of The American College Of Cardiology 2023, 81: 610. DOI: 10.1016/s0735-1097(23)01054-9.Peer-Reviewed Original ResearchCARDIAC REMODELING AFTER INTRAMYOCARDIAL AUTOLOGOUS BONE MARROW MONONUCLEAR CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY: 2-YEAR ECHOCARDIOGRAPHY RESULTS FROM THE CARDIAMP CELL THERAPY HEART FAILURE TRIAL OPEN-LABEL ROLL-IN COHORT
Johnston P, Bellumkonda L, Raval A, Anderson R, Holmes-Higgin D, Pepine C. CARDIAC REMODELING AFTER INTRAMYOCARDIAL AUTOLOGOUS BONE MARROW MONONUCLEAR CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY: 2-YEAR ECHOCARDIOGRAPHY RESULTS FROM THE CARDIAMP CELL THERAPY HEART FAILURE TRIAL OPEN-LABEL ROLL-IN COHORT. Journal Of The American College Of Cardiology 2023, 81: 740. DOI: 10.1016/s0735-1097(23)01184-1.Peer-Reviewed Original ResearchClinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States
Desai N, Sutton M, Xie J, Fine J, Gao W, Owens A, Naidu S. Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal Of Cardiology 2023, 192: 16-23. PMID: 36709525, DOI: 10.1016/j.amjcard.2022.12.030.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyIndex dateCardiovascular eventsIncidence rateSymptomatic obstructive hypertrophic cardiomyopathyAtrial fibrillation/flutterCommon cardiovascular eventMonths continuous eligibilityHealthcare resource utilizationMedicare Supplemental databasesIBM MarketScan CommercialEligible patientsDiagnosis dateMarketScan CommercialClinical outcomesContinuous eligibilityTreatment optionsCumulative riskPatientsResource utilizationPharmacotherapyCardiomyopathyDiseaseNovel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers
Shi T, Miller E. Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers. Current Cardiovascular Imaging Reports 2023, 16: 1-9. PMID: 36926261, PMCID: PMC9996562, DOI: 10.1007/s12410-023-09574-4.Peer-Reviewed Original ResearchCardiac sarcoidosisMyocardial inflammatory diseaseDisease activityImmunomodulatory therapyInflammatory cardiomyopathyMyocardial inflammationInflammatory diseasesPrognostic performanceReviewThe purposeNovel radiotracersMyocarditisSarcoidosisTherapy guidanceInflammationMolecular featuresRadiotracerClinical translationMolecular imagingMolecular mechanismsHigh specificityCardiomyopathyImproved mechanistic insightsPathogenesisTherapyDisease
2022
Electromagnetic interference complicating Impella® use during pediatric ablation
Sullivan J, Maitoza L, Brysiewicz N, Hall E, Beach C. Electromagnetic interference complicating Impella® use during pediatric ablation. Annals Of Pediatric Cardiology 2022, 15: 533-535. PMID: 37152518, PMCID: PMC10158480, DOI: 10.4103/apc.apc_3_22.Peer-Reviewed Original ResearchIncremental Utility of 3D Printing to Guide the Surgical Management of Apical Aneurysm
Layoun H, Akintoye E, Guler E, O’Sullivan K, Krywanczyk A, Tong M, Harb S. Incremental Utility of 3D Printing to Guide the Surgical Management of Apical Aneurysm. JACC Case Reports 2022, 4: 1056-1059. PMID: 36062049, PMCID: PMC9434645, DOI: 10.1016/j.jaccas.2022.06.019.Peer-Reviewed Original ResearchPulmonary Vascular Complication Associated With Coronavirus Infection and Role of Lung Resection
Wong L, Sukumar M, Fuss C, Thanawala R. Pulmonary Vascular Complication Associated With Coronavirus Infection and Role of Lung Resection. The Annals Of Thoracic Surgery 2022, 115: e89-e91. PMID: 35472408, PMCID: PMC9035613, DOI: 10.1016/j.athoracsur.2022.04.016.Peer-Reviewed Original ResearchConceptsPulmonary artery pseudoaneurysmArtery pseudoaneurysmAcute hypoxic respiratory failureHypoxic respiratory failureThoracic surgical proceduresLife-threatening complicationsComplication of ruptureCOVID-19 pneumoniaLung resectionStress cardiomyopathyRespiratory failurePulmonary vasculaturePerioperative planningSurgical proceduresPseudoaneurysmGranulomaPatientsCoronavirus infectionCOVID-19BacteremiaResectionHemothoraxBleedingCardiomyopathyPneumoniaExperiences of athletes with arrhythmogenic cardiac conditions in returning to play
Shapero K, Gier C, Briske K, Spatz ES, Wasfy M, Baggish AL, Pierce S, Ackerman MJ, Lampert R. Experiences of athletes with arrhythmogenic cardiac conditions in returning to play. Heart Rhythm O2 2022, 3: 133-140. PMID: 35496453, PMCID: PMC9043374, DOI: 10.1016/j.hroo.2022.01.009.Peer-Reviewed Original ResearchGenetic heart diseaseSudden cardiac deathMost common diagnosesLong QT syndromeCardiac deathCommon diagnosisHeart diseasePhysicians' knowledgeExperiences of athletesHypertrophic cardiomyopathyCommon sportsCardiac conditionsQT syndromeTelephone interviewsEmergency action planConservative approachDiagnosisAthletesPoor communicationQualitative componentCommon themesCardiomyopathyRegistrySyndromeClinic
2021
Effect of Ischemic Cardiomyopathy on Perioperative Mortality After Endovascular Abdominal Aortic Aneurysm Repair
Bellamkonda K, Zogg C, Nassiri N, Strosberg D, Desai N, Guzman R, Chaar C. Effect of Ischemic Cardiomyopathy on Perioperative Mortality After Endovascular Abdominal Aortic Aneurysm Repair. Journal Of Vascular Surgery 2021, 74: e131-e132. DOI: 10.1016/j.jvs.2021.06.202.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply